Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Annovis Bio (NYSE: ANVS) secured FDA agreement on its buntanetap safety analysis plan for a planned New Drug Application. The FDA agreed that Annovis can pool safety data from four Alzheimer’s and Parkinson’s studies and combine them in standardized datasets for analysis. Annovis plans to build the safety package while the Phase 3 DUET-AD trial and the Parkinson’s extension study are ongoing.
Annovis expects over 1,600 participants to have received buntanetap across the four studies by the 6-month DUET-AD data readout and intends to submit the application after the DUET-AD readout. FDA agreement covers the safety plan only; it does not ensure the application will be accepted for filing or that buntanetap will be approved. Those decisions will depend on the FDA’s review of the complete application, including DUET-AD efficacy and safety results.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA agreement on the safety plan allows Annovis to pool four Alzheimer’s and Parkinson’s studies using standardized analysis datasets
- Moderate point. Forward-looking: it has not happened yet and may not happen.Buntanetap application submission is planned after the DUET-AD readout
- Minor point. Forward-looking: it has not happened yet and may not happen.Safety package preparation is planned while DUET-AD and the Parkinson’s extension study are ongoing
- Minor point. Forward-looking: it has not happened yet and may not happen.Over 1,600 participants are expected to have received buntanetap across the pooled studies by the 6-month DUET-AD readout
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.FDA filing acceptance and drug approval are not assured and depend on full application review, including DUET-AD efficacy and safety results
News Explained
After agreeing to pool safety data, the FDA provided recommendations on statistical methods; Annovis says it will incorporate them into its final ISS plan and submit an updated Study Data Standardization Plan.
Key Figures
- Studies in pooled analysis
- 4 studies
- 3 randomized, double-blind, placebo-controlled studies and 1 open-label extension
- Participants exposed to buntanetap
- over 1,600 participants
- Anticipated by the 6-month DUET-AD data readout
Historical Context
-
Second consecutive positive safety-board recommendation continued DUET-AD without modification after review of 861 patients.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
integrated summary of safety regulatory
new drug application regulatory
pharmacokinetics medical
open-label extension medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- FDA agrees with plan to pool safety data from four Alzheimer’s and Parkinson’s studies and to integrate it at the level of standardized analysis datasets
- Safety package will be built in parallel with ongoing studies; NDA submission planned after DUET-AD data readout
MALVERN, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational once-daily pill for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has agreed to the Company’s Integrated Summary of Safety (ISS) plan, including a proposed strategy to pool safety data from its AD and PD clinical studies and to integrate the pooled data at the level of standardized analysis datasets, in support of its planned New Drug Application (NDA) for buntanetap.
The ISS, an essential part of the drug development process, evaluates a drug’s safety in a large number of patients from multiple clinical trials. To build a more robust safety database, Annovis proposed combining data from its AD and PD programs, based on buntanetap’s common mechanism of action, comparable pharmacokinetics, and similar safety profiles in both diseases. The Company also submitted a draft of the data presentation, integration, and calculation.
In addition, FDA agreed with the Company’s proposal to integrate the pooled data at the level of standardized analysis datasets and provided recommendations on the statistical methods for the integrated analysis. Annovis plans to incorporate FDA’s recommendations into its final ISS statistical plan and submit an updated Study Data Standardization Plan.
The pooled analysis will include three randomized, double-blind, placebo-controlled studies and one open-label extension (OLE) study:
- Completed Phase 3 study in early PD (NCT05357989)
- Completed Phase 2/3 study in mild to moderate AD (NCT05686044)
- Active Phase 3 DUET-AD (NCT06709014)
- Active OLE PD (NCT07284784)
By the 6-month data readout from DUET-AD, Annovis anticipates that over 1,600 participants will have received buntanetap across the pooled studied.
“An NDA has to show not only that a drug works, but that it is safe in a large population treated over a long period,” said Maria Maccecchini, Ph.D., President, Founder and CEO of Annovis. “Because buntanetap acts through the same mechanism in Alzheimer’s and Parkinson’s diseases, FDA’s agreement on pooling and presentation allows us to bring the safety data from both programs together into a single, extensive database. It also means we can build the safety package now, while DUET-AD and OLE PD are still ongoing.”
Annovis intends to submit the NDA following the data readout of DUET-AD.
FDA’s agreement with the pooling strategy does not constitute approval of buntanetap and does not ensure that the NDA will be accepted for filing or approved. FDA will make those determinations based on its review of the complete application, including the efficacy and safety results of DUET-AD.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.